116P Real-world treatment patterns and clinical effectiveness of eribulin in HR+/HER2- metastatic breast cancer patients in the United States
Annals of Oncology(2021)
摘要
Eribulin mesylate was approved in the US in 2010 for metastatic breast cancer (mBC) following at least two chemotherapeutic regimens; prior therapy should include anthracycline and taxane in the adjuvant or metastatic setting. With the changing treatment landscape in HR+/HER2- mBC, the main objective of our analyses was to assess the real-world clinical effectiveness of eribulin in HR+/HER2- mBC, when prescribed consistent with the US label. A retrospective chart review study of mBC patients initiating eribulin per US label between 2011-2017 was conducted across US community oncology practices. De-identified data were extracted by prescribing physicians from patients’ medical records and captured via an electronic case report form. Clinical outcomes assessed included provider-reported best overall response (defined as complete + partial response), progression-free survival (PFS), and overall survival (OS) in the HR+/HER2- mBC patients overall and those treated with eribulin post cyclin-dependent kinase inhibitor (CDKi), respectively. A total of 233 mBC patients with HR+/HER2- subtype treated with eribulin met the study inclusion criteria: mean age was 61 years and 55% had an ECOG status of 0 or 1. Median duration of eribulin treatment was 5.8 months, with 67% treated in 3rd line and 33% in ≥4th line. Best overall response on eribulin was 52% and median PFS for eribulin was estimated at 6.1 months. Landmark OS at 12 and 24 months was 46% and 26%, respectively. Approximately 31% (n=72) of the HR+/HER2- mBC patients had received a CDKi prior to eribulin. In the post CDKi subgroup, median duration of eribulin treatment was 4.5 months, and 74% were treated in 4th line or later. Best overall response on eribulin was 40%. Median PFS for eribulin in the post CDKi subgroup was estimated to be 4.6 months. Landmark OS at 12 and 24 months in the post CDKi subgroup was 39% and 19%, respectively. Results of these retrospective analyses reinforce the clinical effectiveness of eribulin in HR+/HER2- mBC patients including those previously treated with a CDKi, when used in accordance with the eribulin US label in clinical practice.
更多查看译文
关键词
eribulin,breast cancer patients,breast cancer,clinical effectiveness,real-world
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要